Last reviewed · How we verify
CHF 5259
CHF 5259 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4.
CHF 5259 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | CHF 5259 |
|---|---|
| Also known as | glycopyrrolate bromide, Placebo |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Sodium-activated potassium channel inhibitor |
| Target | KCNN4 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By inhibiting KCNN4, CHF 5259 is expected to reduce the excitability of smooth muscle cells and decrease the frequency of atrial fibrillation episodes. This mechanism of action is thought to be beneficial for patients with atrial fibrillation who are at risk of stroke.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration (PHASE1, PHASE2)
- Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers (PHASE1)
- Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients (PHASE2)
- A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease (PHASE2)
- Efficacy of LAMA Added to ICS in Treatment of Asthma (PHASE2)
- Triple in Asthma Dose Finding (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHF 5259 CI brief — competitive landscape report
- CHF 5259 updates RSS · CI watch RSS
- Chiesi Farmaceutici S.p.A. portfolio CI